Oscar Health's Profitability Promise Faces Its Fourth and Final Test

Oscar Health (OSCR) reports first-quarter 2026 earnings before the market opens on May 6, 2026, with analysts expecting the health insurer to deliver $1.21 per share on revenue growth driven by record membership expansion. The central question: can Oscar translate its aggressive market share gains in the Affordable Care Act (ACA) exchanges into sustained profitability after posting a $1.24 loss in Q4 2025? With the stock up 25% over the past three months and options pricing a 10% move, investors are betting the company's 2026 turnaround story will gain traction.

Part 1: Earnings Preview

Oscar Health operates as a technology-driven health insurance company focused on individual and small group markets, primarily through ACA exchanges, serving over 3.4 million members as of early 2026. The company differentiates itself through its proprietary +Oscar technology platform, which emphasizes data analytics, AI-driven care management, and telehealth integration.

Earnings Expectations: Oscar reports Q1 2026 results on May 6, 2026, before market open. Analysts expect earnings of $1.21 per share on revenue estimates that are not disclosed in the data. The company most recently reported Q4 2025 earnings of -$1.24 per share, a significant miss against the -$0.84 consensus. Year-over-year, the $1.21 estimate represents a +31.52% improvement from the $0.92 reported in Q1 2025, signaling expectations for a dramatic profitability inflection.

Key Narrative Themes:

1. Profitability Inflection After Record Losses: Oscar's 2026 guidance projects operating earnings of $250 million to $450 million after posting a $396.4 million operating loss in 2025. Investors are watching whether Q1 marks the beginning of this turnaround, with the $1.21 EPS estimate implying a sharp reversal from the -$1.24 loss just one quarter ago. The company's ability to execute on cost discipline—evidenced by a 160 basis point improvement in SG&A expense ratio to 17.5% in 2025—will be critical.

2. Membership Growth and Market Share Dominance: Oscar achieved record membership of approximately 3.4 million as of February 2026 and doubled its ACA market share from 17% in 2025 to 30% in 2026. The question is whether this explosive growth—driving projected 61% revenue growth to $18.7-$19.0 billion in 2026—can be monetized profitably, or whether aggressive pricing to capture share will pressure margins.

3. Medical Loss Ratio Management and Rate Increases: With an 88.5% medical loss ratio (MLR) as of September 2025 and a planned 28% weighted average rate increase for 2026, investors are focused on whether Oscar can balance competitive pricing with margin expansion. The company's AI-driven care management tools are positioned as key to controlling medical costs while maintaining member satisfaction.

Analyst Commentary: Analysts remain cautious despite the growth story. The consensus rating sits at 3.00 (Hold) with a $16.00 average price target, implying limited upside from current levels around $17.94. Commentary highlights concerns about Oscar's historical inability to achieve sustained profitability despite strong top-line growth, with some analysts noting that the 2026 guidance—while optimistic—still requires flawless execution on cost management and rate adequacy. The market is in "wait and see" mode, demanding concrete evidence that membership gains will translate to bottom-line results.

Part 2: Historical Earnings Performance

Oscar Health has demonstrated a mixed but improving earnings track record over the past four quarters. The company beat estimates in three of the four most recent quarters—posting surprises of +10.84% in Q1 2025, +1.11% in Q2 2025, and +3.64% in Q3 2025—before delivering a significant -47.62% miss in Q4 2025 with -$1.24 versus the -$0.84 consensus.

The pattern reveals a company navigating seasonal volatility in the health insurance business. Q1 2025's $0.92 result marked a rare profitable quarter, while Q2 and Q3 saw losses that nonetheless came in slightly better than feared. The Q4 miss broke this positive momentum, with the -$1.24 loss representing a sharp deterioration that raised questions about cost control and medical cost trends heading into the critical 2026 enrollment period.

The trend suggests Oscar can execute operationally during stable periods but faces challenges during quarters with elevated medical utilization or enrollment-related expenses. With analysts now expecting $1.21 for Q1 2026—a dramatic swing from the prior quarter's loss—the company faces high expectations to prove its profitability inflection thesis is real rather than aspirational.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Oscar Health typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Oscar Health exhibits high volatility around earnings, with an average absolute Day 0 move of 8.35% and Day +1 follow-through averaging 4.73%. The stock's post-earnings behavior has been particularly dramatic in recent quarters: Q1 2025 saw a massive +30.22% Day 0 surge after the company posted its first profitable quarter, while Q4 2024 delivered a -12.28% decline following disappointing results.

The 12.18% average Day 0 range indicates substantial intraday volatility as traders digest results and guidance, with Day +1's 9.60% average range showing continued price discovery. Recent quarters show a pattern where positive surprises generate outsized gains (Q1 2025's 30% jump, Q3 2025's 7% Day +1 follow-through), while misses trigger sharp but more contained selloffs. Investors should prepare for significant price swings, with the direction heavily dependent on whether Oscar demonstrates tangible progress toward profitability.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of ±10.00% ($1.79) through the May 8 weekly expiration, slightly above the 8.35% average historical Day 0 move but well below the stock's demonstrated capacity for extreme reactions. Given Q1 2025's 30% surge and the high stakes around profitability inflection, the options market may be underpricing potential volatility if results significantly beat or miss the aggressive $1.21 EPS estimate.

Part 3: What Analysts Are Saying

Analysts maintain a cautious stance on Oscar Health heading into earnings, with the consensus rating at 3.00 (Hold) and an average price target of $16.00—implying 10.8% downside from the current $17.94 price. The rating distribution shows a divided Street: 1 Strong Buy, 1 Moderate Buy, 7 Holds, 1 Moderate Sell, and 1 Strong Sell among 11 analysts covering the stock.

Sentiment has improved over the past month, with the average recommendation ticking up from 2.91 to 3.00 and one analyst upgrading from Moderate Sell to Hold. However, the improvement is marginal, reflecting persistent skepticism about Oscar's ability to deliver on its ambitious 2026 profitability targets. The $11.00 to $23.00 price target range illustrates the wide dispersion of views, with bears citing ongoing execution risks and bulls betting on the company's technology platform and market share gains.

The $16.00 consensus target sitting below the current price suggests analysts believe the recent rally—up 25% over three months—has priced in much of the optimistic scenario. For the stock to sustain current levels or move higher, Oscar will need to not only meet the $1.21 EPS estimate but also reaffirm full-year guidance and demonstrate tangible margin improvement.

Part 4: Technical Picture

Oscar Health enters earnings with strengthening technical momentum after a sharp reversal in sentiment. The Barchart Technical Opinion currently shows a 40% Buy signal, up dramatically from 24% Buy one week ago and flipping from 88% Sell one month ago, indicating a significant shift in near-term momentum.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates powerful near-term momentum heading into the earnings release
• Medium-term (50% Sell): Moderate sell signal suggests intermediate-term resistance and caution about sustainability
• Long-term (50% Buy): Moderate buy signal reflects improving longer-term trend structure after the recent rally

Trend Characteristics: The trend is characterized as Weak and Weakening, suggesting the recent momentum surge lacks conviction and may be vulnerable to reversal if earnings disappoint.

The stock is trading at $17.94, positioned above its 10-day ($17.63), 20-day ($16.52), 50-day ($14.36), and 100-day ($14.67) moving averages, but above the 200-day moving average at $15.98. This alignment above key moving averages typically signals bullish momentum, though the stock recently pulled back from the 5-day moving average at $18.28, suggesting some near-term consolidation.

The technical setup presents a double-edged sword heading into earnings. The strong short-term buy signal and positioning above all major moving averages provide a supportive backdrop if results meet or exceed expectations. However, the "Weak" and "Weakening" trend characterization, combined with the medium-term sell signal, suggests the rally is fragile and vulnerable to sharp reversal on any disappointment. With the stock trading above the $16.00 analyst price target and having rallied 25% in three months, much of the optimistic case appears priced in, leaving limited room for error.